Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult ...

There’s a reason that the most successful genre on the home market has been the same for over a generation now: People love action movies. They allow us to escape reality and enter a world where ...

The combination of gemcitabine, cisplatin, plus nivolumab represents a new first-line treatment ... revolving around immunomodulatory mechanisms of action of cisplatin, and synergy of these mechanisms ...

If you’re in the mood for an action-packed thriller, Netflix’s latest release, “Counterattack,” might be just what you’re looking for. This Mexican movie dropped on the streaming service ...